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Abstract
“Oral cancer” is a term usually describing oral cavity and oropharyngeal malign tumors. 
The most histologic type of carcinoma is squamous cell carcinoma, seen in oral and oro-
pharyngeal region with the incidence of 90%. Prevention or early diagnosis of prema-
lignant and oral cancer requires increased public awareness and educating practitioners 
to be skillful in identifying oropharyngeal region pathology. To prevent oral cancers, 
the etiological factors should be known, and measures must be taken according to those 
factors. Premalignant lesions are leukoplakia, lichen planus in oral and cutaneous form, 
erythroplakia, stomatitis nicotina, and submucous fibrosis. Premalignant lesions should 
be treated, if possible, or followed up on carefully. To date, there are many clinical, his-
topathological, radiological, and optical techniques to diagnose or capture precancerous 
and oral cancer lesions early. The routine management of oral cancers is firstly surgical 
resection with or without postoperative adjuncts and other therapies such as the use of 
postoperative chemoradiation and radiation. Successful treatment of oral cancer patients 
is a complex issue that requires a multidisciplinary approach, including oral and maxil-
lofacial surgeons, oral and maxillofacial radiologists, ENT specialists, medical and radio-
logical oncologists, prosthodontists, dentists, speech therapists, supportive care experts, 
and also pathologists or, if possible, oral and maxillofacial pathologists.
Keywords: oral squamous cell carcinoma, preventive actions, early diagnosis, 
management of oral cancer, multidisciplinary approach, improving quality of life
1. Introduction
“Oral cancer” is a term usually used to describe oral cavity and oropharyngeal malign tumors. 
Oropharyngeal cancers  include the regions known as buccal mucosa, hard-soft palate, and floor 
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of mouth—gums, tonsils, and base and oral tongue remain oropharynx regions [1]. Despite 
this, the typical use of the term “oropharyngeal cancer” is unsuitable for this current topic due 
to earlier determination of “oral cancer.” Although some reverse knowledge is in the litera-
ture, incidence of pharyngeal cancers is increasing, while oral cancer is declining in the USA 
according to the recent LeHew et al. report [1]. In addition, they connected this issue to human 
papillomavirus (HPV) and how it may cause many more pharyngeal cancers than oral cancers, 
while heavy alcohol consumption and tobacco use also cause more oral cancer. The same author 
emphasized ethnicity, gender, age, and other demographic factors that influence the occurrence 
of pharyngeal or oral cancers [1–4]. The other paper published by Yadav [2] mentioned the 
increase of oral or mouth cancer in young individuals, especially female individuals, and that 
lifestyles affect the likelihood it occurs (such as smoking or chewing tobacco, chewing betel 
nuts). On the other hand, lip cancer occurrence is increasing because of ozone layer loss [2].
The International Agency for Research on Cancer determined 25 years ago that types HPV 
16–18 had a carcinogenic effect in humans which were responsible for the huge proportion 
(90%) of carcinoma of the cervix. HPV 16–18 had also been an etiologic factor related to vari-
ous head, neck, and also oral carcinomas [5]. Fortunately, as relatively consolatory features 
of HPV-related cancers, Ang et al. [6] and Yadav [2] reported that these cancers are more 
sensitive to the current treatment options and have higher survival rates than other different 
etiologic factors, such as tobacco, causing carcinomas. Some of the other etiologic factors have 
mostly been seen in Southern Chinese ancestry: nasopharyngeal cancer, Epstein-Barr virus 
(EBV) exposure, and also consumption of salted fish [7].
Worldwide, oral cancer cases are meanly estimated at 500,000, with nearly 389,000 new cases 
per year and nearly 130,000 deaths [3, 4, 8]; 45,000 oral cancer cases in the USA face nearly 
8500 deaths, and in the European Union, there are nearly 66,650 new cases faced each year 
[1, 3]. In further information found in the literature, Sri Lanka, India, Pakistan, Bangladesh, 
Hungary, and France show higher rates of new cases [3]. In addition to this information, 
South and Southeast Asian countries such as Pakistan, India, the Philippines, and Bangladesh 
are 80% of the newest cases due to increasing tobacco use and alcohol consumption and espe-
cially in Malaysian betel quid chewing [7–9].
The most histological type of carcinoma is squamous cell carcinoma, seen in the oral and 
oropharyngeal region with 90% [3, 7, 10–18]. The histological variants of squamous cell car-
cinomas are revealed in the literature to be adenosquamous, verrucous squamous, basaloid 
squamous, and papillary squamous cell carcinomas. In addition, carcinoma in situ is the pre-
vious form of the invasive squamous cell carcinomas. The other type of carcinoma of oropha-
ryngeal mucosa in basal cells is seen rarely, in the oral cavity under 5%. On the other hand, 
there are many types of epithelial malignancies, such as mucoepidermoid carcinoma with 
54%, low-grade adenocarcinoma with 17%, and adenoid cystic carcinoma with 15% mostly in 
hard palate minor salivary glands (60%), lips (25%), and vestibular mucosa (15%). Moreover, 
tumors being aggressive in any part of the body, mucosal melanomas are rarely seen in the 
hard palate and gingiva. Bony tumors, such as very rare cases of ameloblastic carcinoma, 
can be seen in the oral region [3]. Lymphomas and all aspects of sarcomas and odontogenic 
tumors, as those have a different etiology, are managed with different methods [17].
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In this chapter, detection, diagnosis, multidisciplinary management, and post-management 
of patients with oral cancer and improvement of their quality of life will be used, instead of 
oral squamous cell cancer terms.
Prevention of oral cancer is an essential goal worldwide; if it is not possible to achieve this, 
then we should detect or diagnose oral cancer in early stages to completely manage it [1]. 
Prevention or early diagnosis of this entity requires public awareness action and practitioner 
education to be skillful in identification of oropharyngeal region pathology [4, 8].
Severity or aggression of a disease, usually termed in the literature as “stage,” is essential to 
treating it in secure conditions without any recurrence. In addition, if it features severe aspects, 
it needs aggressive treatment modality such as surgical eradication and a reconstruction pro-
cess. In body regions wherein cancer occurs, the classifications, severity, and level determina-
tion systems differ. The most popular system evaluating cancer type and severity is the TNM 
system according to two recent American Joint Committee on Cancer (AJCC) editions, the 
seventh and eighth [13, 19], used the world over due to its simplicity and friendly aspect [3]. 
The eighth edition has been in use since January, 2018. Additionally, the eighth edition differs 
from previous editions because it has taken HPV into account as an etiological factor [19].
In the head and neck region, the classification of cancer has been standardized with TNM 
levels or a stage grouping system and a histological aspect, meaning the histological grading 
of a disease [5, 20]. Oral cancers are also included in this system [3].
The patients diagnosed with oral cancer early should start treatment immediately, as soon as 
possible, to not worsen the prognosis. At advanced stages, oral cancer (especially in stages III 
and IV) has a very low survival rate at 9–50% [2, 4, 14]. According to some literature, 30% of 
patients’ efforts to seek out or find professional help for about 3 months without any interven-
tion to malignancy but 1 month of delaying causes stage advancing and also dramatically 
reduces odds of survival [4, 21].
Diagnoses of oral cancer have been carried out to date by using clinical, radiological, and 
histopathological tools. In recent years, new technological tools and biomarkers have begun 
promising use as tools to diagnose oral cancer early. It can be caught in stages of cancer as 
early as stages I and II [10]. In addition, nanotechnology has started to see its use in diag-
nosing oral cancer [15]. Besides this, biomarkers were suggested to be used in detecting the 
malign transformation potential of premalignant lesions such as oral leukoplakia [22].
The other issue: public awareness about premalignant lesions and formed oral cancer is very 
important to prevent or to cure them without any morbidity or threat to life [3, 4, 8, 22]. Public 
awareness about self-inspection of the mouth tissue and individuals recognizing the appearance 
of oral cancer is crucial [3, 4]. Fortunately, in the literature, there are many actions taken on this 
topic [2, 8] that should be continued by healthcare providers; also, world governments should 
support healthcare providers’ works and actions [1, 4, 8, 22] because the prognosis of oral cancer 
is continuing to worsen survival rates due to utilizing these pathologies at advanced stages [22].
Oral cancer has still been challenging for public health and requires significant, demanding 
efforts [2, 3, 7, 23, 24]. The management of oral cancer is a complex issue that requires a 
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multidisciplinary approach, including oral and maxillofacial surgeons, oral and maxillofacial 
radiologists, ENT specialists, medical and radiological oncologists, prosthodontists, den-
tists, general surgeons, primary care clinicians (such as family medicine), physical therapy 
and rehabilitation specialists, dietitians, speech therapists, supportive care experts, and also 
pathologists or, if possible, oral and maxillofacial pathologists [2, 24, 25].
After radical, surgical, and other treatment modalities such as radiotherapy and chemotherapy— 
especially in stages III and IV patients—improving a patient’s quality of life is very important 
[7, 14, 24, 26, 27]. Besides these, if patients have more advanced surgical (and other) treatment 
modality, the important thing is, of course, survival. Also, the second issue is improving qual-
ity of life. In this aspect, prosthodontics, speech therapy, dental implant-supported restora-
tion with oral and maxillofacial surgeons, and other supportive specialties such as providers 
like physical therapists, mental health professionals, and dietitians and applications improve 
a patient’s quality of life [2, 24].
2. Preventive awareness and control care for oral cancers
Preventive medicine acts as a unique control for oral cancers and also charges at all-time 
low costs to states across the world [2, 15]. In this way, many actions can be taken by health 
organizations, especially by the World Health Organization in the risky geographic regions of 
the world [28]. Prevention of oral cancer is mainly a management of those diseases, so public 
awareness should be the first priority for health workers (e.g., by using media to promote fast 
outcomes) [3, 14]. For awareness about encountering precancerous lesions [1, 22, 28], Jeihooni 
et al. [9] reported that 30.4% of patients had preventable oral cancer, while 50% did not, and 
the remaining 19.6% of patients were unclear as to whether or not oral cancer is preventable.
To prevent oral cancers, the etiological factors should be known, and measures must be taken 
according to those causes. Etiological factors are tobacco use, especially in individuals older 
than 40 years of age, alcohol consumption, betel chewing, HPV infection or carriage, dietary 
intakes such as salted meat consumption, poor oral hygiene, genetic predisposition, Epstein-
Barr virus (EBV) infection, long-term exposure to sunlight, and immune system disease such 
as organ transplant recipients and HIV-infected patients, especially as it causes lip cancer [1, 
3, 4, 9, 13, 14, 29, 30].
HPV-related oral cancers, especially oropharyngeal cancers, differ from other cause-related 
cancers as HPV-related cancers have been seen in young, non- or former tobacco users, 
nonalcoholic patients, and also patients with small T tumors but with nodal involvement 
(fortunately, their prognosis is more satisfactory than non-related HPV tumors). In addition, 
HPV-related tumors are well-defined borderline, more exophytic with smaller sizes and lymph 
node metastasis with dominant cystic features [19]. To prevent HPV-related oral cancers, vac-
cination against HPV should be performed to decrease the incidence of oropharyngeal SCC 
[31], whereas Owosho et al. [31] reported that HPV-related oropharyngeal cancer reached its 
highest rate in the year 2006 and has since started to decline but not at a statistically significant 
rate. In the literature, vaccination programs have primarily focused on HPV infection related 
Prevention, Detection and Management of Oral Cancer54
to cervical cancer [1]. Thus, Center for Disease Control and Prevention (CDC) is recommend-
ing that the vaccination program for HPV-related oropharyngeal cancers should be carried 
out for children at ages 11–12 in two doses by health providers [31].
Other efforts to prevent oral cancer should be done by controlling tobacco use or reduction 
programs [3, 6, 7, 11, 14, 29]. Alcohol consumption should be reduced or cut off as well [3, 7, 
14]. If tobacco and alcohol are used together by the same individuals, that increases the oral 
cancer rate and may be a dramatically worse prognosis than HPV-related cancers [3, 5, 7, 
11]. Unfortunately, alcohol is related to a very risky factor for cancer occurring even in non-
smoking individuals [3, 5, 7].
On the other hand, improving especially rich vegetable and fruit diet intake awareness pro-
grams, physical activity-increasing programs in daily life, regular sexual education for ado-
lescents, and oral hygiene education activities may be helpful for reducing oral cancer rates in 
the future [1, 14, 32]. Awareness programs and activities should be conducted by healthcare 
providers or governments worldwide, especially in more risky regions such as Southeast 
Asia. For example, images of early oral cancer can be placed on cigarette packages [4].
In the risky region, or those patients that have high risk, they should be encouraged to carry 
out self-inspection of their oral mucosa, and if they see any mouth abnormality, they are 
obligated to take professional advice or treatment [4]. In addition, oral hygiene education and 
encouragement to improve it in individuals are key factors in preventing or early detection 
of oral cancer [9]. Moreover, Rahmati-Najarkolaei et al. [32] reported that awareness activities 
with students about risky factors decreased fear of oral cancer and also changed their attitude 
about knowing whether they have oral cancer. Lack of public awareness about cancer-causing 
factors and predictors produces diagnosis of oral cancer at stages as late as III or IV [4]. 
Therefore, awareness may provide early diagnosing of lesions; it reduces the cost of treatment 
and also reduces treatment morbidity [16, 22].
To date, many strategies have experimented with community awareness in the literature, such 
as mass media campaigns, which have gained some success from increased public awareness 
[1, 3, 8]. Unfortunately, these improvements are still not enough in terms of public aware-
ness. Nowadays, Internet-based or online connections such as social media are very popular 
communication tools across the whole world. For example, the online-supported education or 
activities for tobacco cessation counseling revealed limited success in a randomized experiment 
[1, 8]. Internet-based education also applied for alcohol counseling with some success gained 
[1]. Billboards have also not been successful in delivering improved awareness to risky popula-
tions [1]. Prevention is the main management of oral cancers, and public awareness is a key part 
of prevention: where, when, and how it should be done and how it is possible is not important.
2.1. Look and see: precancerous mouth lesions
Many types of oral lesions have malignant transformation potential, aptly named premalig-
nant or precancerous lesions. Premalignant lesions are described by using clinical, patho-
logical, histochemical, and also many other screening techniques for which lesions such as 
leukoplakia, lichen planus with oral and cutaneous form, erythroplakia, stomatitis nicotina, 
Early Detection and Multidisciplinary Approach to Oral Cancer Patients
http://dx.doi.org/10.5772/intechopen.81126
55
and submucous fibrosis are named or classified [3, 10, 15, 18, 22, 33–35]. In addition, there is 
less malign transformation potential in lesions such as discoid lupus erythematosus and also 
a lesser likelihood of malignant transformation in hereditary entities such as epidermolysis 
bullosa and dyskeratosis congenita [34]. For the lip cancer, there are precancerous lesions 
like xeroderma pigmentosum, radiodermatitis, and chronic cheilitis [18]. However, histologi-
cal investigation has only produced knowledge about malignant transformation potential—
named dysplasia—and has been indicated or used as a prediction of malignant changes [34]. 
According to the WHO’s (2005) statement, carcinoma in situ has the highest degree of dyspla-
sia and is also defined as a premalignant lesion [3, 10, 34]. Premalignant lesions are usually 
clinically screened for mouth mucosa such as white, red, or red-white mixed patches and are 
also called leukoplakia or erythroplakia [34, 35].
3. Early diagnosis of precancerous and oral cancer lesion techniques
Early detection of premalignant lesions and also cancer lesions is a crucial issue for the head 
and neck region, as the late diagnosing rate of 60% worldwide causes huge surgical and 
oncological interventions or low survival rate [14, 15, 36]. To date, there are many clinical, 
histopathological, radiological, and optical techniques to diagnose or capture precancerous 
and oral cancer lesions, such as vital tissue staining (toluidine blue stain), exfoliative cytol-
ogy, OralCDx (OralCDx Laboratories, Suffern, NY) or Orcellex® (Rovers Medical Devices, 
BV, the Netherlands), brush cytology, and cell markers or biomarkers. There are also many 
new developments of novel real-time in vivo imaging and spectroscopy-based devices: high-
resolution microendoscopy (HRME), autofluorescence imaging (AFI), targeted fluorescence 
imaging (TFI), and optical coherence tomography (OCT); also, there are other optical visu-
alization methods such as ViziLite Plus with Orascoptic DK (Orascoptic, a Kerr Company, 
Middleton, Wis.), VELscope™ (Visually Enhanced Lesion Scope, LED Dental, White 
Rock, British Columbia, Canada), Microlux DL (AdDent, Danbury, Conn.), ViziLite (Zila 
Pharmaceuticals), TBlue (Zila Pharmaceuticals, Phoenix), Raman spectroscopy (RS), elastic 
scattering spectroscopy (ESS), narrowband imaging (NBI), diffuse reflectance spectroscopy 
(DRS), and confocal reflectance microscopy (CRM) in addition to normal biopsy of the tissue 
with histopathological investigation [12, 15, 16, 28, 34–38].
These techniques are local detectors of lesions. Besides these, oral cancer may spread region-
ally and may also have distant metastasis. For instance, to make stage determining and 
treatment strategies for lesions, imaging systems as computed tomography (CT), magnetic 
resonance imaging (MRI), cone beam computerized tomography (CBCT), and positron emis-
sion tomography (PET) can be useful to scan the head and neck region for regional spread of 
oral cancer [15]. These techniques are divided into two categories, as either lesion detection 
or lesion assessment. Whether these tests have been tested across several works, however, 
remains questionable [37].
Toluidine blue stain is a metachromatic thiazine material that binds to DNA in alcohol and 
water. Toluidine blue (TB) is a member of the thiazine group of metachromatic dyes, which 
binds to DNA and is partially soluble both in water and in alcohol. Theoretically, dysplastic 
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and malignant cells have higher nucleic acid content; hence, it is stained with dyes that can 
be identified under the microscope due to nucleic acid and have been used since 1980 [34]. 
Toluidine blue stain, ViziLite, and VEL scope sensitivity and specificity in oral dysplasia 
patients are presented by Awan et al. [37] to be 84.1 and 77.3%, 15.3 and 27.8%, and 65.8 and 
56.8%, respectively.
Exfoliative cytology procures cells from a wide surface area of the affected tissue with fewer 
invasive effects on the tissue than biopsy. It also involves a lower contamination risk prior to 
DNA obtaining than surgical intervention [5]. Exfoliative cytology is obtained by scrapping the 
mucosa lesion using a blade as tongue blade. The obtained material is spread on a dry, clean 
glass lam and fixed with 100% ethanol. The lam is then sent to an experienced pathologist for 
examination under a light microscope for dysplastic evidences in the cells [35]. In addition, 
serum and saliva are the most commonly used as less invasive, easily accessible, cost-effective, 
and convenient samples for cancer detection [15]. The sensitivity and specificity of exfoliative 
cytology for oral cancer detection were revealed as 93.5 and 50.6%, respectively [15]. Although 
exfoliative cytology is less invasive, it is highly subjective and dependent upon the expertise 
of examiners. Moreover, exfoliative cytology related to the DNA aneuploidy and quantitative 
cytomorphometry has low specificity due to the collection of disassembled cells [15]. If the 
exfoliative cytology is used on heavy smoker and alcohol-using patients with negative malig-
nancy findings, a biopsy procedure should be carried out as an additional supportive test [22].
OralCDx or Orcellex® brush cytology is a bit advanced for complementary forms of the exfo-
liative cytology, due to it including representative cells of all layers of epithelial tissue [34, 38]. 
Moreover, brush cytology has provided diagnostic accuracy because of computer assistance 
screening [34, 38]. Studies demonstrated that OralCDx or Orcellex® cytology has a potential 
value as an adjunct to oral diagnosing or screening in identifying premalignant pathologies 
at early stages that provides surgical or curative treatment that is most effective [39]. In the 
future, developing automatic, cytometric, or cytomorphometric techniques combined with 
genetic and related features may enhance screening strategies [34]. Affecting tissue with any 
pathology sample technique is still recommended if there is a strong suspicion of any lesion 
with malignancy regardless of the oral brush cytology result [34].
Biological, chemical, or reactional molecular agents named cell markers and biomarkers 
mean that signs of living organisms and the obviousness of their availability as tumor necro-
sis factor-alpha (TNF-α), epithelial growth factor (EGFR), vascular endothelial growth factor 
(VEGF), IL-8 and IL-8 mRNA, and interleukin 6 (IL-6) [10, 15]. Biomarker investigation of 
abnormalities of oral tissues as normal, tumorous, and inflammatory keratinocyte proteomes 
is likely to find new biomarker agents for oral cancer diagnosis, treatment, follow-up, and 
the development of personalized therapies for oral cancer and other tumorous regions [16].
The most visible oral premalignant or precancerous lesion is oral leukoplakia (OL) that has 
been studied for its establishment of a biomarker that signals the malign transformation of 
OL [22]. For instance, OL has low prevalence in western countries, so the development of a 
new biomarker is challenging due to the low rate of malignant transformation, and it requires 
long follow-up periods to achieve a new biomarker [22]. Besides these, loss of heterozygosity 
(LOH) was described as the strongest and most valuable biomarker by Mao et al. at the end 
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of the twentieth century. They reported that OL housing LOH at 3p14 or 9p21 was related to 
the 37% chance of developing invasive cancer compared with only 6% in lesions without these 
biomarkers [22]. Dysplasia is a very important sign of OL malign transformation; however, 
it does not mean that it will transform into a malign lesion, such as an oral squamous cell 
carcinoma lesion. Detecting or signaling oral leukoplakia malignant-transforming biomarkers 
is crucial in the future. Chemoprevention actions or works using retinoid evoked unique pro-
spective gathering of biodata that led to the development of biomarkers [22]. Evidence-based 
studies showed that a visual examination of oral regions may be a cost-effective screening 
model, and finding adjunct auxiliaries and biomarkers is becoming more popular [28].
Hence, if the environmental conditions could be changed, oral leukoplakia may be reversible 
even with advanced dysplasia, which does not change into any malign lesion such as OSCC 
[22]. However, the existence of dysplasia is often the important criterion that affects clinical 
treatment of oral leukoplakia [22].
Microendoscopy (HRME) is a novel in vivo optical imaging and spectroscopy-based tool that 
has the content to provide an early diagnosis of cancer in real time. This tool is a cost-effective 
and noninvasive technique for point-of-care detection of premalignant and cancer in body 
regions including the oral cavity and hypopharynx. The HRME technique provides direct 
screening of malignant indicators such as nuclear crowding, pleomorphism, and elevated 
nuclear-to-cytoplasmic area ratio. This technique has almost identical possibility with cytol-
ogy and invasive biopsy procedures. The HRME technique therefore has a promising devel-
opment in the future [36, 40].
The ViziLite system, as an oral optical lumenoscopy technique alone or in combination with 
other techniques mentioned above, has been used successfully in the last decade. The US 
Food and Drug Administration has received a combination of both ViziLite and TB systems 
(ViziLite Plus with TBlue System; Zila, Batesville, AR, USA), as an adjunct to visual screen-
ing of the oral cavity. This combined technique for detecting or diagnosing premalignant or 
cancerous lesions provides almost the same level of outcome that invasive method biopsy and 
histopathological investigation provide [15, 22, 34, 37].
VELscope™ (LED Dental, White Rock, British Columbia, Canada) is noninvasive and directly 
screens the changes of tissue autofluorescence characteristic screening tools in the oral cavity [12, 22]. 
It uses blue light between 400 and 460 nm wavelengths to influence the endogenous fluoro-
phores. Because of its simplicity, it does not require any special training on the system and can 
be used in daily general subspecialty practice. Farah et al. [41] reported that VELscope™ screen-
ing did not provide a definitive diagnosis on the existence of epithelial dysplasia, so VELscope™ 
is not reliable for detecting epithelial dysplasia without clinical examination. In contrast to the 
Farah et al. [41] report, the other study carried out by Awan et al. [42] reported that VELscope™ 
is useful in confirming the existence of erythroplakia, oral leukoplakia, and other soft tissue 
diseases, but it cannot discriminate between low-risk and high-risk pathologies [34].
Raman spectroscopy (RS), a common optical diagnostic technique, works with vibrational 
spectroscopies that discriminate normal mucosa and malignant pathologies by reflecting vari-
ables within tissues and returning optical signals [15]. However, this optical tool’s original yet 
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subjective finding outcomes depend on the practitioners’ evaluation experience [15]. Stone et al. 
[43] first applied the Raman spectroscopy in the head and neck region in 2000 to investigate 
the laryngeal mucosa by comparing with normal biopsy procedures in 15 patients. According 
to this study, RS produced a specificity of 90 and 92% sensitivity for detecting squamous cell 
carcinoma [43]. We may thus conclude that the RS technique is useful for daily practice.
3.1. Multidisciplinary approach to diagnosis and management of precancerous and 
oral cancer lesions: healthcare providers and patients’ role
Early diagnosis, a crucial issue as mentioned above, is very easy, but across the world, oral 
cancer is being detected in late stage due to its subtlety in early stage [3]. The routine manage-
ment of oral cancer is first surgical resection, with or without postoperative adjuncts and 
other therapies used as part of postoperative chemoradiation and radiation. This approach of 
combining multiple treatments has increased survival rates in the last decade.
Successful treatment of oral cancer patients is a complex issue that requires multidisciplinary 
approaches, including oral and maxillofacial surgeons, oral and maxillofacial radiologists, 
ENT specialists, medical and radiological oncologists, prosthodontists, dentists, general sur-
geons, primary care clinicians (such as family medicine), physical therapy and rehabilitation 
specialists, dietitians, speech therapists, supportive care experts, and also pathologists or, 
if possible, oral and maxillofacial pathologists [2, 3, 24, 25]. In addition, multidisciplinary 
approaches to oral cancer patients allow for the maximization of reliable oncologic control 
and also minimize morbidities such as patient function and form [3].
Early diagnosis of oral cancer is vital for a patient’s survival rate and also for future quality 
of life. In addition, a dentist has an important role in initial diagnosing of any pathology in 
the oral region because of daily oral health practice [2, 14, 43]. So, any ignorance on behalf of 
dentists’ education and daily practice is a crucial phenomenon for detecting any lesions in 
early phase. If a dentist has detected any abnormality of oral tissue in an emergency situation, 
he or she should perform a biopsy procedure or immediately refer the patients to advanced 
specialties such as oral and maxillofacial surgeons, otolaryngologists, or advanced oncologi-
cal-trained oral and maxillofacial surgeons, if it is possible [2, 14].
In a majority of world regions, the oral and maxillofacial surgery specialty is based on den-
tistry education and is concerned with diagnosis, medical and surgical, and advanced treat-
ment of disease, disorders, injuries, and malformation, including the functional and esthetic 
features of the oral and maxillofacial region’s soft and hard tissues and related neighboring 
structures [2]. Oral and maxillofacial surgeons take part in the biopsy, which checks whether 
it is a true- or false-positive diagnosis; advanced radiological imaging is required to investi-
gate in this stage of pathology. In addition, they surgically treat precancerous lesions and also 
take part in the treatment of early-stage cancer.
A case with a 67-year-old male patient was referred to an experienced oral and maxillofacial 
surgeon and diagnosed with oral leukoplakia. The patient was treated with a diode laser 
using evaporation mode. According to the follow-up period, no recurrence has been revealed 
with the patient in healthy oral condition (Figures 1 and 2).
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Figure 2 . Postoperative laser treatment view of oral leukoplakia (Case 1 patient).
Figure 1 . Prelaser treatment of oral leukoplakia (Case 1 patient).
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If the OMF surgeon has not accrued enough experience for more extensive pathology, he or 
she should refer patients to trained or sufficiently experienced head and neck surgeons such 
as an oral and maxillofacial surgeon, ear nose throat surgeon, general surgeon, or a plastic 
surgeon; plastic surgeons and oral and maxillofacial surgeons have a duty to perform pre-
prosthetic surgery, revision surgery, and also dental and oral and maxillofacial implants to 
rehabilitate the oral cavity for speech improvement, swallowing, mastication, and esthetic 
appearance. In addition, oral and maxillofacial surgeons promote maxillofacial prosthodon-
tists for the construction of maxillofacial and oral prosthesis [2].
Oral and maxillofacial oncology training was part of a related oral and maxillofacial surgery 
residency program for about 3–4 years, following the 5–6 years for a basic dentistry degree. 
In addition, these specially trained people take an additional 1 or 2 years’ oncological surgery 
training for cancer surgery and rehabilitation and reconstruction surgery such as regional 
vascular flap reconstruction, e.g., a pectoralis major flap with five to six costal grafts, a latissi-
mus dorsi muscular flap with scapular graft, and other regional soft and hard tissue vascular 
flaps to reconstruct mandibular and maxillary resection defects are used. In addition, distant 
vascular-free flaps such as perineal musculocutaneous with fibula and an anterior radial fore-
arm flap are used to reconstruct maxillary and mandibular oncologic resected defects by oral 
and maxillofacial oncologic program surgeons. On the other hand, the oncologic oral and 
maxillofacial surgeon training program includes core rotations on resection and reconstruc-
tion surgery, medical oncology, and radiation oncology. They also carry out duties like edu-
cating others in the dental profession on cancer screening and management. They take part in 
the oncological multidisciplinary team, including pathologists, radiologists, ENT specialists, 
and other professions [2].
The transoral access is a common surgical approach to precancerous pathologies and super-
ficial cancers of anterior portions of the mouth, tongue, and alveolus. In the posterior region 
of the mouth, an invasive approach is needed, especially if there is a limitation due to inade-
quate surgical view and trismus. Median lip-split paramedian mandibulotomy access is used 
for tumor management of the posterior mouth region. In addition, midfacial degloving and 
upper cheek access are typically useful for maxillary tumors [3].
Neck dissection is a very important part of oral cancer surgical management. Fortunately, 60% 
of cases with an early-stage tumor have clinically negative neck metastasis. Unfortunately, 
nearly 20–30% of entities have microscopically prominent neck nodal metastasis according to 
elective neck dissection (END). Nodal metastasis risk occurs for several reasons. One, cervical 
lymph node metastasis can reduce the survival rate by 50% when compared with similar 
primary tumors, excepting cervical or other regions. Tongue cancer on the mouth floor is 
more likely to advance into the neck lymph node; thus, these cases should require elective 
neck dissection, even if they are in an early stage.
The maxillary gum and hard palate have relatively lower chances of neck metastasis occur-
ring, and if this is determined to be the case, there is no need for END to be indicated [3].
Isolated node biopsy is an adjunct alternative to END for determining the stage of a cN0 neck 
in the T1–T2 stage of SCCOC [3, 44]. This method was first carried out in 2001 by Shoaib et al. 
[44], and it has been used by several other studies in Europe and the USA. However, this 
Early Detection and Multidisciplinary Approach to Oral Cancer Patients
http://dx.doi.org/10.5772/intechopen.81126
61
technique requires experienced practitioners to be able to carry out the procedure. It should 
therefore be done in select centers with experienced doctors [3].
If patients are clinically or radiographically determined to have positive neck nodes, a com-
prehensive neck dissection should be done involving level I to V dissection. The requirement 
to sacrifice important structures like the sternocleidomastoid muscle, spinal accessory nerve, 
and internal jugular vein depends on the location of the nodal metastasis and its features [44]. 
A common type of wide neck dissection is the modified radical neck dissection, named MRND 
type 1. MRND, as a treatment choice, is a rarely selected option due to direct infiltration of 
Figure 3 . Prereconstruction dentures’ view of Case 2 patient’s oral structures after a maxillary cancer operation.
Figure 4 . Maxillomandibular dentures’ view of Case 2 patient.
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the gross extranodal structures [3]. A patient with clinically negative neck node metastasis 
has metastasis risk mainly throughout levels I to III. Therefore, supraomohyoid neck dissec-
tion (SOHND) is usually enough for these diseases. However, patients with primary tongue 
squamous cell carcinoma require neck dissection level IV and may be obligated due to the 
likelihood of skip metastasis [3].
Oral pathologists and oral medicine specialists also play key roles in oral cancer prevention, 
diagnosing, early management, and follow-up procedures. They perform the biopsy proce-
dures in oral pathologies that identify lesions; hence, strategies are formed for the manage-
ment process of the detected lesion [2].
Maxillofacial prosthodontists take part in key positions in management specifically to restore 
the function of jaws and maxillofacial tissue after tumor eradication. To improve the patients’ 
psychological condition, they replace the functional and cosmetic defects with prosthetic con-
struction carried out by prosthodontics in the maxillofacial region [2].
Case 2 features a 78-year-old male patient who underwent total maxillectomy due to squa-
mous cell carcinoma. With an oral and maxillofacial surgeon’s guidance, to improve the life 
quality of the patient, the maxillomandibular dentures were constructed by an experienced 
prosthodontist. The patient is chewing and eating smoothly, and he is still under the control 
period in uneventful condition (Figures 3–5).
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